Cannabinoid Withdrawal Is Caused by Receptor Competition, Not Inverse Agonism
Both an inverse agonist (rimonabant) and a neutral antagonist precipitated withdrawal in cannabis-dependent mice, showing that withdrawal is caused by rapid receptor competition rather than rimonabant's inverse agonist properties.
Quick Facts
What This Study Found
Researchers developed a mouse model of cannabinoid dependence using the potent, long-acting cannabinoid AM2389 and compared withdrawal precipitated by three different antagonists.
Both rimonabant (inverse agonist) and AM4113 (neutral antagonist) precipitated withdrawal signs, while AM6545 (a peripherally restricted antagonist that does not enter the brain) did not. This demonstrated two key points: withdrawal is centrally mediated (brain-based), and the inverse agonist properties of rimonabant are not responsible for withdrawal.
Withdrawal was caused by rapid competition for CB1 receptor binding, meaning the antagonist quickly displaces the agonist from the receptor. This was confirmed when reinstating AM2389 or THC reversed withdrawal symptoms.
Key Numbers
AM2389 more potent and longer-acting than THC; both rimonabant and AM4113 precipitated withdrawal; AM6545 (peripheral only) did not; withdrawal reversed by AM2389 or THC reinstatement
How They Did This
Mouse study using AM2389 for dependence induction. Acute characterization with tetrad tests. Tolerance measured after repeated dosing. Withdrawal precipitated by three antagonists with different pharmacological properties. Reversal tested with AM2389 and THC.
Why This Research Matters
Understanding that cannabinoid withdrawal is caused by receptor competition rather than inverse agonism has implications for developing cannabis addiction treatments. Neutral antagonists may be therapeutically useful without the additional risks of inverse agonists.
The Bigger Picture
Rimonabant was withdrawn due to psychiatric side effects partly attributed to its inverse agonist activity. This study suggests that neutral antagonists like AM4113 could be developed as potentially safer treatments for cannabis dependence, though they would still precipitate withdrawal.
What This Study Doesn't Tell Us
Mouse model may not fully replicate human cannabinoid dependence. Used a very potent synthetic cannabinoid (AM2389) rather than THC for dependence induction. The psychiatric side effects of rimonabant may involve mechanisms beyond withdrawal precipitation.
Questions This Raises
- ?Would neutral CB1 antagonists have fewer psychiatric side effects than rimonabant in humans?
- ?Could gradual antagonist dosing prevent withdrawal precipitation?
- ?Is the AM2389 dependence model relevant to real-world cannabis dependence?
Trust & Context
- Key Stat:
- Peripheral-only CB1 antagonist did not cause withdrawal; brain-penetrating ones did
- Evidence Grade:
- Well-designed pharmacological study distinguishing mechanisms of withdrawal, but limited to a mouse model with a synthetic cannabinoid.
- Study Age:
- Published in 2015. Neutral CB1 antagonist development for addiction treatment continues.
- Original Title:
- Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
- Published In:
- Psychopharmacology, 232(15), 2751-61 (2015)
- Authors:
- Tai, Sherrica(2), Nikas, Spyros P(6), Shukla, Vidyanand G(2), Vemuri, Kiran, Makriyannis, Alexandros, Järbe, Torbjörn U C
- Database ID:
- RTHC-01066
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What causes cannabis withdrawal?
This study showed withdrawal is caused by rapid displacement of cannabinoids from CB1 receptors in the brain. When an antagonist quickly takes the receptor away from the agonist, withdrawal symptoms occur. The process is centrally (brain) mediated.
Could this lead to a cannabis addiction treatment?
Potentially. The finding that neutral antagonists can precipitate and potentially manage withdrawal without the extra effects of inverse agonists like rimonabant suggests a safer pharmacological approach to cannabis dependence treatment.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- anger-irritability-quitting-weed-withdrawal
- appetite-after-quitting-weed
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- caffeine-weed-withdrawal
- cannabinoid-hyperemesis-syndrome
- cannabis-withdrawal-complete-guide
- cannabis-withdrawal-severity-levels-mild-moderate-severe
- cannabis-withdrawal-syndrome
- cannabis-withdrawal-syndrome-dsm-5
- cannabis-withdrawal-syndrome-timeline-day-by-day
- cannabis-withdrawal-vs-alcohol-nicotine-opioid-comparison
- creativity-without-weed-quitting-artist-musician
- emotional-after-quitting-weed-crying
- first-week-quitting-weed
- hobbies-after-quitting-weed
- how-long-does-weed-withdrawal-last
- how-long-to-feel-normal-after-quitting-weed
- identity-after-quitting-weed
- leaving-stoner-culture-identity
- marijuana-withdrawal-symptoms
- money-saved-quitting-weed-calculator
- night-sweats-quitting-weed-withdrawal
- one-year-sober-weed
- paws-cannabis-post-acute-withdrawal
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- weed-cravings
- weed-depersonalization-derealization
- weed-paws-withdrawal
- weed-withdrawal-anger
- weed-withdrawal-brain-fog
- weed-withdrawal-chest-tightness-heart-palpitations
- weed-withdrawal-crying-emotional
- weed-withdrawal-depression
- weed-withdrawal-headaches
- weed-withdrawal-irritability
- weed-withdrawal-men
- weed-withdrawal-mood-swings
- weed-withdrawal-nausea
- weed-withdrawal-night-sweats
- weed-withdrawal-no-appetite
- weed-withdrawal-sweating-detox
- weed-withdrawal-timeline
- weed-withdrawal-vs-alcohol
- weed-withdrawal-women
- what-happens-when-you-stop-smoking-weed
Cite This Study
https://rethinkthc.com/research/RTHC-01066APA
Tai, Sherrica; Nikas, Spyros P; Shukla, Vidyanand G; Vemuri, Kiran; Makriyannis, Alexandros; Järbe, Torbjörn U C. (2015). Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.. Psychopharmacology, 232(15), 2751-61. https://doi.org/10.1007/s00213-015-3907-0
MLA
Tai, Sherrica, et al. "Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.." Psychopharmacology, 2015. https://doi.org/10.1007/s00213-015-3907-0
RethinkTHC
RethinkTHC Research Database. "Cannabinoid withdrawal in mice: inverse agonist vs neutral a..." RTHC-01066. Retrieved from https://rethinkthc.com/research/tai-2015-cannabinoid-withdrawal-in-mice
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.